Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.jval.2010.10.016

Abstract

Infliximab represents a cost-effective treatment option well within the National Institute for Health and Clinical Excellence threshold relative to palliative care. In light of equivalent outcomes with other tumor necrosis factor α inhibitors, its position in the treatment pathway is likely to be governed by treatment cos

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Briggs, Professor Andrew
Authors: Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A., and Fenwick, E.L.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Value in Health
ISSN:1098-3015

University Staff: Request a correction | Enlighten Editors: Update this record